$TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Healthcare
Sector
Biotechnology
Industry
Daniel Bensen
CEO
60
Employees
$36.29
Current Price
$1.49B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $528,506.16 | 14,295 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $528,506.16 | 14,295 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 3 | $791,470.67 | 22,295 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $1,019,656.33 | 30,295 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | KAPLAN GILLA Director | Sale | 14,295 | $36.97 | $528,506.16 | View Details |
| Feb 12, 2026 | Bensen Daniel Chief Discovery Officer | Sale | 5,872 | $33.37 | $195,928.68 | View Details |
| Feb 12, 2026 | Bensen Daniel Chief Discovery Officer | Sale | 2,128 | $31.50 | $67,035.83 | View Details |
| Jan 12, 2026 | Bensen Daniel Chief Discovery Officer | Sale | 1,017 | $29.08 | $29,575.17 | View Details |
| Jan 12, 2026 | Bensen Daniel Chief Discovery Officer | Sale | 6,983 | $28.44 | $198,610.49 | View Details |
20 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.55
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$ETNB โ 89bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$JANX โ Janux Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.$MLYS โ Mineralys Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$BCAX โ Bicara Therapeutics Inc.via RA CAPITAL MANAGEMENT, L.P.